Weighing In: Actual vs Ideal vs Adjusted Body Weight to Calculate Dose of Melphalan in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
More than one-third of Adults in the United States are obese. Obesity plays a significant role in chemotherapy dosing. The literature on how or if doses should be modified is conflicting and scant. Some evidence has shown that dose reductions related to obesity, while reducing toxicities, may result in decreased survival outcomes. High-dose Melphalan is the standard chemotherapy regimen used in autologous stem cell transplantation for multiple myeloma. There are no established guidelines about the methods of calculating the final dose of Melphalan based on patients’ weight. This issue is of particular importance because of the current epidemic of obesity and because of the known association between MM and obesity.
|Weighing In: Actual vs Ideal vs Adjusted Body Weight to Calculate Dose of Melphalan in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
|All rights reserved
|August 13, 2015